(127) found that treatment of ALK fusion NSCLC cell lines (H3122, H2228, and MGH006) with recombinant NRG1 protein (ligand of HER3) resulted in resistance to the ALK TKI TAE684, which was eliminated by co-administration of TAE684 and the HER2 inhibitor lapatinib, demonstrating that the ligand of HER3, NRG1, can mediate resistance of ALK fusion NSCLC to ALK TKIs through the activation of the HER3/HER2 signaling pathway. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.